Advertisement
Loading...

Ocugen, Inc.

OCGNNASDAQ
Healthcare
Biotechnology
$1.34
$-0.01(-0.74%)
U.S. Market opens in 0h 37m
Advertisement

Ocugen, Inc. Fundamental Analysis

Ocugen, Inc. (OCGN) shows moderate financial fundamentals with a PE ratio of -5.99, profit margin of -16.05%, and ROE of -1279.88%. The company generates $0.0B in annual revenue with moderate year-over-year growth of 8.83%.

Key Strengths

PEG Ratio0.32
Current Ratio1.86

Areas of Concern

ROE-1279.88%
Operating Margin-14.84%
We analyze OCGN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -129173.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-129173.6/100

We analyze OCGN's fundamental strength across five key dimensions:

Efficiency Score

Weak

OCGN struggles to generate sufficient returns from assets.

ROA > 10%
-1.26%

Valuation Score

Excellent

OCGN trades at attractive valuation levels.

PE < 25
-5.99
PEG Ratio < 2
0.32

Growth Score

Moderate

OCGN shows steady but slowing expansion.

Revenue Growth > 5%
8.83%
EPS Growth > 10%
-15.00%

Financial Health Score

Moderate

OCGN shows balanced financial health with some risks.

Debt/Equity < 1
5.74
Current Ratio > 1
1.86

Profitability Score

Weak

OCGN struggles to sustain strong margins.

ROE > 15%
-127987.50%
Net Margin ≥ 15%
-16.05%
Positive Free Cash Flow
No

Key Financial Metrics

Is OCGN Expensive or Cheap?

P/E Ratio

OCGN trades at -5.99 times earnings. This suggests potential undervaluation.

-5.99

PEG Ratio

When adjusting for growth, OCGN's PEG of 0.32 indicates potential undervaluation.

0.32

Price to Book

The market values Ocugen, Inc. at 73.97 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

73.97

EV/EBITDA

Enterprise value stands at -6.97 times EBITDA. This is generally considered low.

-6.97

How Well Does OCGN Make Money?

Net Profit Margin

For every $100 in sales, Ocugen, Inc. keeps $-16.05 as profit after all expenses.

-16.05%

Operating Margin

Core operations generate -14.84 in profit for every $100 in revenue, before interest and taxes.

-14.84%

ROE

Management delivers $-1279.88 in profit for every $100 of shareholder equity.

-1279.88%

ROA

Ocugen, Inc. generates $-1.26 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.26%

Following the Money - Real Cash Generation

Operating Cash Flow

Ocugen, Inc. generates limited operating cash flow of $-62.76M, signaling weaker underlying cash strength.

$-62.76M

Free Cash Flow

Ocugen, Inc. generates weak or negative free cash flow of $-62.94M, restricting financial flexibility.

$-62.94M

FCF Per Share

Each share generates $-0.19 in free cash annually.

$-0.19

FCF Yield

OCGN converts -13.13% of its market value into free cash.

-13.13%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.99

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.32

vs 25 benchmark

P/B Ratio

Price to book value ratio

73.97

vs 25 benchmark

P/S Ratio

Price to sales ratio

101.59

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

5.74

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.86

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1279.88

vs 25 benchmark

ROA

Return on assets percentage

-1.26

vs 25 benchmark

ROCE

Return on capital employed

-1.83

vs 25 benchmark

How OCGN Stacks Against Its Sector Peers

MetricOCGN ValueSector AveragePerformance
P/E Ratio-5.9929.06 Better (Cheaper)
ROE-127987.50%733.00% Weak
Net Margin-1605.22%-53111.00% (disorted) Weak
Debt/Equity5.740.38 Weak (High Leverage)
Current Ratio1.864.02 Neutral
ROA-125.95%-19397.00% (disorted) Weak

OCGN outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Ocugen, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

3737.37%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-16.25%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-44.81%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ